Recent Advances in Gene Therapy for Hemophilia

Pharmacy Tech CEU
notesMonograph
Contact Hours: 1.0 (0.1 CEUs)

Course Summary

Hemophilia is a hemorrhagic disease characterized by a deficiency in blood clotting. It results from gene mutations in the genes that encode clotting factor proteins that form blood clots. The disease manifests itself in excessive and prolonged periods of external and internal bleeding. The conventional hemophilia treatment replaces missing blood clotting factors through intravenous infusion of plasma and cryoprecipitates (plasma-derived) and recombinant clotting factor concentrates. While these agents and treatments are effective, the current gene therapy strategies may offer new alternatives to the replacement protocols. Recent gene therapy directions, including viral, non-viral, and gene-editing technologies, are often more effective and provide new therapeutic avenues for routine hemophilia treatment.


Course Objectives

Provide an overview of hemophilia types and characteristics

Describe the diagnosis of hemophilia

Describe the current treatment options for hemophilia

Describe pharmacological gene therapy approaches for hemophilia

Discuss current challenges in gene therapy for hemophilia


I. Introduction

II. Definition and Prevalence of Hemophilia

III. Causes of Hemophilia

IV. Symptoms of Hemophilia

V. Diagnosis of Hemophilia

VI. Other Treatment Products

VII. Gene Therapy of Hemophilia

VIII. Challenges of Gene Therapy

IX. Patient Counseling

X. Future Trends in Gene Therapy

XI. Summary

How to Earn Credit:
To earn credit for this course, participants must:
  1. Read the course objectives and faculty planner disclosure
  2. Read the course material
  3. Complete the post-test with a minimum score of 70% and complete the course evaluation form.
  4. Results are automatically submitted to CPE Monitor

Faculty Planner Disclosure

The following individuals were involved in developing this activity: Salam Kadhim, PhD, and Pamela Sardo, PharmD, BS. Salam Kadhim, PhD, was a senior scientist at Inmed Pharmaceuticals until July 1, 2022. Pamela Sardo, PharmD, BS, was an employee of Rhythm Pharmaceuticals until March 2022. There are no financial relationships relevant to this activity to report or disclose by any of the individuals involved in the development of this activity.


Unlabeled Use Disclosures

The information provided in this course is general in nature and it is solely designed to provide participants with continuing education credit(s). This course and materials are not meant to substitute for the independent, professional judgment of any participant regarding that participant’s professional practice, including but not limited to patient assessment, diagnosis, treatment and/or health management. Medical and pharmacy practices, rules, and laws vary from state to state, and this course does not cover the laws of each state; therefore, participants must consult the laws of their state as they relate to their professional practice. Healthcare professionals, including pharmacists and pharmacy technicians, must consult with their employer, healthcare facility, hospital, or other organization, for guidelines, protocols, and procedures they are to follow. The information provided in this course does not replace those guidelines, protocols, and procedures but is for academic purposes only, and this course’s limited purpose is for the completion of continuing education credits. Participants are advised and acknowledge that information related to medications, their administration, dosing, contraindications, adverse reactions, interactions, warnings, precautions, or accepted uses are constantly changing, and any person taking this course understands that such person must make an independent review of medication information prior to any patient assessment, diagnosis, treatment and/or health management. Any discussion of off-label use of any medication, device, or procedure is informational only and such uses are not endorsed hereby. Nothing contained in this course represents the opinions, views, judgments, or conclusions of RxCe.com LLC. RxCe.com LLC is not liable or responsible to any person for any inaccuracy, error, or omission with respect to this course, or course material.

Computer Hardware/Software Requirements

Please ensure the device you plan to use meets these requirements and specifications:

  • Operating System: Windows 7,8,10, or 11 /Mac OS X 10.9 or later/iOS/Android
  • Supported Browsers: Microsoft Edge, Firefox, Google Chrome, Safari, Opera
  • A connection to the internet
  • For Live Webinars or Conferences: GoToWebinar application for iOS, Android, Mac, or PC. You cannot 'call into' a live conference.

star star star star star ) ) star )

Rating: 5/5

Based on the ratings of 24 customers

  • Target Audience: Pharmacy Tech
  • Contact Hours: 1.0 (0.1 CEUs)
  • Activity Release Date: 9/12/2023
  • Activity Expiration Date: 9/12/2026
  • Activity Type: Knowledge
  • UAN: 0669-0000-23-145-H01-T
  • Topic: Disease State Management/Drug Therapy
  • CeBroker Number: 20-1105990

Author:

Salam Kadhim, PhD

AUTHOR BIO

VIEW PDF VIEW AS WEB PAGE

The logo for the Accreditation Council for Pharmacy Education (ACPE).

RxCe.com, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The logo for the Pharmacy Technician Certification Board (PTCB).
PTCB Course Recognition

RxCe.com, LLC, offers pharmacy technician continuing education courses for PTCB recertification. Pharmacy technician courses are indicated both in the Target Audience description and the ACPE UAN which will end with a "T".

‹‹ Back to Course List